Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
Nalmefene, alcohol dependence
Naloxone opioid overdose treatment injection or intranasal treatment
Naltrexone for antipsychotic-induced weight gain gambling disorder preventing relapse after alcohol detoxification borderline personality disorder for tardive dyskinesia people with learning difficulties preventing relapse after opioid detoxification
Naranjo adverse drug reaction scale (adapted) 972
Naranjo scale antipsychotics in menopausal women anticholinergic effects of antipsychotics Summary of psychiatric adverse effects of non-psychotropics
National Confidential Inquiry into Suicide and Homicide by People with Mental Illness
National Institute for Health and Care Excellence (NICE) guidelines attention deficit hyperactivity disorder in adults borderline personality disorder depression generalised anxiety disorder obsessive compulsive disorder prophylaxis in bipolar disorder anxiety spectrum disorders attention deficit hyperactivity disorder in children and adolescents dementia eating disorders hypercholesterolaemia panic disorder
Neurobiology of withdrawal
Neuroleptic malignant syndrome association Neuroleptic malignant syndrome relative efficacy treatment of negative symptoms optimal dosage treatment algorithm
new psychoactive substances (NPS/designer drugs) 477 Drug-induced excited state Benzodiazepine misuse
Natural
Neuroleptic malignant syndrome
Next-steps if no response
Nicotine attention deficit hyperactivity disorder drug interactions Nicotine schizophrenia depression and anxiety movement disorders psychotropic effects smoking cessation and withdrawal symptoms
Nicotine dependence bupropion electronic vaping devices Nicotine and smoking cessation treatment algorithms withdrawal symptoms cytisine Nicotine nicotine replacement therapy varenicline
nicotine replacement therapy (NRT) 523-524 adverse effects combination of formulations clinical effectiveness preparations and doses
Nicotine vaping devices (vaping) 527-528 adverse effects Nicotine and smoking cessation clinical effectiveness preparations and doses
Nocebo effects, patient expectations of treatment
Non-adherence impacts rates and degrees of adherence lithium restarting psychotropic medications after period of non-compliance
non-competitive N-methyl-D-aspartate receptor antagonists
Non-nucleoside reverse transcriptase inhibitors
non-steroidal anti-inflammatory drugs (NSAIDs)
Nucleoside reverse transcriptase inhibitors, psychiatric adverse reactions
Nutritional supplements fatigue in multiple sclerosis anorexia nervosa
NICE guidelines
Nicotine preparations and doses
Nocturnal enuresis, management
Non-iatrogenic benzodiazepine dependence
Non-psychotropics associated with QT prolongation (see Crediblemeds.org for latest information; this is not a complete list).
Norclozapine